Insight Molecular Diagnostics Inc. (IMDX) - Total Liabilities
Based on the latest financial reports, Insight Molecular Diagnostics Inc. (IMDX) has total liabilities worth $51.12 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Insight Molecular Diagnostics Inc. growing its equity to track the company's year-over-year net asset growth rate.
Insight Molecular Diagnostics Inc. - Total Liabilities Trend (2013–2025)
This chart illustrates how Insight Molecular Diagnostics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See IMDX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Insight Molecular Diagnostics Inc. Competitors by Total Liabilities
The table below lists competitors of Insight Molecular Diagnostics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EDAP TMS SA
NASDAQ:EDAP
|
USA | $61.96 Million |
|
Rockfields Property Indonesia Pt
JK:ROCK
|
Indonesia | Rp114.49 Billion |
|
Cartesian Growth Corporation II Class A Ordinary Shares
NASDAQ:RENE
|
USA | $20.70 Million |
|
Borosil Scientific
NSE:BOROSCI
|
India | Rs978.97 Million |
|
Zig Sheng Industrial Co Ltd
TW:1455
|
Taiwan | NT$3.39 Billion |
|
Sebang
KO:004360
|
Korea | ₩292.28 Billion |
|
Axactor SE
OL:ACR
|
Norway | Nkr930.72 Million |
|
Humasis Co. Ltd
KQ:205470
|
Korea | ₩90.75 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Insight Molecular Diagnostics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Insight Molecular Diagnostics Inc. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Insight Molecular Diagnostics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Insight Molecular Diagnostics Inc. (2013–2025)
The table below shows the annual total liabilities of Insight Molecular Diagnostics Inc. from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $57.22 Million | +20.83% |
| 2024-12-31 | $47.35 Million | -12.99% |
| 2023-12-31 | $54.42 Million | -10.04% |
| 2022-12-31 | $60.50 Million | -35.88% |
| 2021-12-31 | $94.35 Million | +330.10% |
| 2020-12-31 | $21.94 Million | +143.17% |
| 2019-12-31 | $9.02 Million | +48.01% |
| 2018-12-31 | $6.09 Million | +4.85% |
| 2017-12-31 | $5.81 Million | +26.78% |
| 2016-12-31 | $4.58 Million | +98.14% |
| 2015-12-31 | $2.31 Million | -68.86% |
| 2014-12-31 | $7.43 Million | +59.03% |
| 2013-12-31 | $4.67 Million | -- |
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expre… Read more